{"id":42974,"date":"2022-06-01T06:40:23","date_gmt":"2022-06-01T06:40:23","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=42974"},"modified":"2022-06-01T07:45:16","modified_gmt":"2022-06-01T07:45:16","slug":"long-acting-cabotegravir-to-be-licensed-for-generic-access","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/42974","title":{"rendered":"ViiV licenses long-acting cabotegravir (CAB-LA) for generic access"},"content":{"rendered":"
<\/div>\n
\n

Simon Collins, HIV i-Base<\/span><\/strong><\/p>\n<\/div>\n

\n

On 26 May 2022, ViiV Healthcare announced that it will now add long-acting cabotegravir injections (CAB-LA) to the Medicines Patent Pool (MPP) for use as PrEP. [1]<\/span><\/strong><\/p>\n<\/div>\n

\n

This will enable other manufacturers to make generic versions of this innovative and important new option to protect against HIV.<\/span><\/p>\n<\/div>\n

\n

This is similar to the company’s licensing of oral dolutegravir for generic use in HIV treatment (ART).<\/span><\/p>\n

ViiV say they will be “working at pace with MPP to execute the licence, building on the experience of our valued and long-standing partnership. We are excited about this important step forward which reflects ViiV\u2019s commitment to voluntary licensing as an integral part of our access to medicines strategies.”<\/p>\n

The announcement follows recent high-profile demands from community activists for early and widespread access to long-acting PrEP in lower- and middle-income countries (LMICs). [2]<\/span><\/p>\n<\/div>\n

\n

These demands were based on impressive results from clinical studies reporting higher rates of adherence and protection in international studies. They were also driven by concerns that access to CAB-LA in LMICs looked extremely limited unless it was available at a comparable price to oral PrEP.<\/span><\/p>\n<\/div>\n

\n

It is also based on research from the Clinton Health Access Initiative (CHAI) showing that generic formulations of CAB-LA injections could be produced at around $15-23 for a year’s course of six injections. [3]<\/span><\/p>\n<\/div>\n

\n

This would be more cost effective (and more effective) than voluntary medical male circumcision which has been widely available for many years.<\/span><\/p>\n<\/div>\n

\n

comment<\/span><\/h3>\n<\/div>\n
\n

The announcement is welcomed and matches earlier commitments by ViiV Healthcare to license dolutegravir to MPP for global access to integrase inhibitor based ART.<\/span><\/strong><\/p>\n<\/div>\n

\n

This agreement also works well for ViiV Healthcare, who initially were unable to identify generic manufactures, although later said they were more open to this approach. [5]<\/span><\/strong><\/p>\n<\/div>\n

\n

It also ensures ViiV meets the commitment to make sure that medicines need to be available in countries where approval studies were run.<\/span><\/strong><\/p>\n<\/div>\n

\n

References<\/p>\n<\/div>\n

\n
    \n
  1. ViiV Healthcare. ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to medicines patent pool. (27 May 2022).
    \n<\/span>https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2022\/may\/viiv-healthcare-commits-to-grant-voluntary-licence-for-patents<\/a><\/li>\n
  2. AfroCAB. Communities demand ViiV\/GSK accelerate access to CAB-LA in LMICs. (1 March 2022).
    \n    http:\/\/www.afrocab.info\/2022\/03\/communities-demand-viiv-gsk-accelerate-access-to-cab-la-in-lmics (link page)<\/a>
    \n    http:\/\/www.afrocab.info\/wp-content\/uploads\/2022\/03\/CAB-LA-Community-Statement-Final_v2.pdf<\/a> (PDF statement)<\/li>\n
  3. Ripin D. Approach for delivery of long-acting ARVs for treatment and prevention in LMICs: cabotegravir as a precedent-setting case study. LEAP conference, March 2022.
    \n    https:\/\/longactinghiv.org\/files\/inline-files\/DavidRipin-LEAP2022.mp4<\/a> (MP3 recording)<\/li>\n
  4. ViiV Healthcare. ViiV\u00a0Healthcare open to voluntary licensing as part of approach to enable greater access to cabotegravir la for prep in low- and middle-income countries. (March 2022)
    \n    https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/company-statements\/viiv-healthcare-statement-on-voluntary-license\/<\/a><\/li>\n<\/ol>\n

    This report was first published on 27 May 2022.<\/em><\/p>\n<\/div>\n

    \n

    \u00a0<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base On 26 May 2022, ViiV Healthcare announced that it will now add long-acting cabotegravir injections (CAB-LA) to the Medicines Patent Pool (MPP) for use as PrEP. [1] This will enable other manufacturers to make generic versions …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,38,10],"tags":[],"class_list":["post-42974","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals","category-treatment-access","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=42974"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42974\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=42974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=42974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=42974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}